Jun 14, 2026Metabolic Therapeutics

Tirzepatide vs. Semaglutide: More Fat Loss, Not Proven Appetite Edge

A 28-week head-to-head trial found greater weight and fat loss with tirzepatide than semaglutide 1 mg—but appetite superiority remains unproven.

tirzepatidesemaglutideweight losstype 2 diabetes

Read article →

Apr 5, 2026Nutrition

Citrus Flavonoids With Metformin: One Small Trial

Can citrus flavonoids improve prediabetes outcomes on metformin? One small trial found lower OGTT glucose, but replication and safety data are missing.

metformincitrus flavonoidsprediabetesglucose control

Read article →

Mar 27, 2026Metabolic Health

Tirzepatide and MASH: Can Weight Loss Track Liver Healing?

Tirzepatide resolved MASH on biopsy in phase 2 data. Can 10% weight loss, triglycerides, and MRI markers help track liver response?

tirzepatidemashliver fibrosisweight loss

Read article →

Mar 27, 2026Nutrition

Oral Semaglutide and Fatty Liver: What a 28-Week Trial Shows

Can oral semaglutide help fatty liver disease? A 28-week obesity trial found weight loss and lower liver stiffness, but fibrosis evidence remains incomplete.

semaglutideglp-1liver fibrosisnafld

Read article →

Mar 21, 2026Neuroprotection

Do GLP-1 Drugs Lower Seizure Risk? An Early Signal

GLP-1 receptor agonists showed fewer seizure events in diabetes trials, but sparse data, stroke effects, and weak endpoints limit conclusions.

glp-1ozempicvictozaseizure risk

Read article →

Mar 21, 2026Cardiovascular Health

GLP-1 Drugs and Stroke: What the Evidence Actually Shows

Do GLP-1 drugs lower stroke risk? Randomized trials show fewer ischemic strokes in high-risk type 2 diabetes, while hemorrhagic and obesity data remain uncertain.

glp-1semaglutideischemic strokecardiovascular outcomes

Read article →

Mar 21, 2026Mental Health

GLP-1 Drugs and Vascular Dementia: A Signal, Not Proof

GLP-1 receptor agonists may reduce vascular dementia risk, but randomized evidence remains imprecise. What the stroke data and cohorts actually show.

glp-1semaglutidevascular dementiaozempic

Read article →

Mar 21, 2026Obesity Drugs

Obesity Drug Guidelines: What GRADE Says Actually Works

New GRADE obesity guidelines rank tirzepatide and semaglutide highest, but indirect comparisons, lean-mass loss, cost, and access still matter.

glp-1semaglutidetirzepatideweight loss drugs

Read article →

Mar 18, 2026Nutrition

Isomaltulose vs. Sucrose: A Modest Glucose Advantage

Isomaltulose may lower the 60-minute glucose peak by about 8 mg/dL versus sucrose. Here is what meta-analyses show—and what they cannot prove.

isomaltulosepostprandial glucosesugar substitutesglycemic index

Read article →

Mar 13, 2026Nutrition

Cellular Chickpea Flour May Raise GLP-1, but Evidence Is Early

Cellular chickpea flour raised GLP-1 in one small bread trial. Learn how intact plant cells may slow digestion—and why appetite claims remain unproven.

glp-1chickpea flourpostprandial glucosecellular microstructure

Read article →

Mar 13, 2026Sleep

Tirzepatide for Sleep Apnea: Big Results, Unproven Mechanism

Tirzepatide cuts sleep-apnea severity in trials, largely through weight loss. Does it help beyond weight loss? The evidence has not proved it.

tirzepatidesleep apneaglp-1weight loss

Read article →

Mar 1, 2026Hormones

GLP-1 Drugs and Heart Failure: Benefit Seems to Depend on Obesity

GLP-1 drugs cut cardiovascular death broadly, but heart failure hospitalization benefit appears limited to obese patients. Here's what the evidence shows.

glp-1semaglutidetirzepatidehfpef

Read article →

Page 1 of 2Next →